Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lymphocyte antigen 6 complex, locus E (LY6E) has been implicated in the malignant progression of various types of cancers; however, the underlying mechanism remains unclear. Here, we identified LY6E as an activator of HIF-1 and revealed their mechanistic and functional links in malignant tumor growth. The aberrant overexpression of LY6E increased HIF-1α gene expression principally at the transcription level. This, in turn, led to the expression of the pro-angiogenic factors, VEGFA and PDGFB, through decreases in the expression levels of PTEN mRNA and subsequent activation of the PI3K/Akt pathway. The LY6E-HIF-1 axis functioned to increase tumor blood vessel density and promoted tumor growth in immunodeficient mice. LY6E expression levels were significantly higher in human breast cancers than in normal breast tissues, and were strongly associated with the poor prognoses of various cancer patients. Our results characterized LY6E as a novel conductor of tumor growth through its modulation of the PTEN/PI3K/Akt/HIF-1 axis and demonstrated the validity of targeting this pathway for cancer therapy.

Original publication

DOI

10.18632/oncotarget.11670

Type

Journal article

Journal

Oncotarget

Publication Date

04/10/2016

Volume

7

Pages

65837 - 65848

Keywords

PTEN/PI3K/Akt/HIF-1 axis, hypoxia-inducible factor 1 (HIF-1), locus E (LY6E), lymphocyte antigen 6 complex, tumor hypoxia, Animals, Antigens, Surface, Apoptosis, Biomarkers, Tumor, Breast Neoplasms, Cell Proliferation, Female, GPI-Linked Proteins, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Mice, Mice, Inbred BALB C, Mice, Nude, Neovascularization, Pathologic, PTEN Phosphohydrolase, Phosphatidylinositol 3-Kinases, Prognosis, Proto-Oncogene Proteins c-akt, Signal Transduction, Survival Rate, Tumor Cells, Cultured, Xenograft Model Antitumor Assays